Secondary prevention for patients following a myocardial infarction: summary of NICE guidance
- PMID: 17569811
- PMCID: PMC1994451
- DOI: 10.1136/hrt.2007.124321
Secondary prevention for patients following a myocardial infarction: summary of NICE guidance
Abstract
Mortality from coronary heart disease has been falling in the UK since the 1970s, but remains higher than in most other Western countries. Most patients receive some treatment for secondary prevention after myocardial infarction, but not all patients are offered the most effective secondary prevention package. The recently published NICE guideline for secondary prevention in patients after myocardial infarction, summarised in this article, makes clear recommendations for management of patients after myocardial infarction, based on best available evidence. The guidelines update the 2001 NICE guideline, and have expanded and emphasised the recommendations for physical activity, dietary and other lifestyle changes, and cardiac rehabilitation, and updated the recommendations for drug therapy.
Conflict of interest statement
Competing interests: All authors were members of the Guideline Development Group for the NICE guideline for secondary prevention after myocardial infarction. Dr Skinner was the clinical advisor, Dr Cooper the lead systematic reviewer and Professor Feder chaired the guideline development group. During the last 5 years Dr Skinner has received travel grants to attend educational meetings from Novartis, Pfizer and Sanofi Synthelabo/Bristol Myers Squibb Pharmaceuticals, with none during the last 2 years.
Comment in
-
Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.Heart. 2007 Jul;93(7):864-6. doi: 10.1136/hrt.2007.124305. Heart. 2007. PMID: 17569812 Free PMC article. No abstract available.
Similar articles
-
Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.Heart. 2007 Jul;93(7):864-6. doi: 10.1136/hrt.2007.124305. Heart. 2007. PMID: 17569812 Free PMC article. No abstract available.
-
An intervention to improve secondary prevention of coronary heart disease.Arch Intern Med. 2007 Mar 26;167(6):586-90. doi: 10.1001/archinte.167.6.586. Arch Intern Med. 2007. PMID: 17389290 Clinical Trial.
-
[Secondary prevention after myocardial infarction].Orv Hetil. 2002 Sep 15;143(37):2117-28. Orv Hetil. 2002. PMID: 12434627 Review. Hungarian.
-
Interventions to improve guideline compliance following coronary artery bypass grafting.Surgery. 2006 Oct;140(4):541-7; discussion 547-52. doi: 10.1016/j.surg.2006.05.014. Epub 2006 Sep 6. Surgery. 2006. PMID: 17011901
-
[Pharmacological prevention of coronary relapses in Italian clinical practice: a literature review].G Ital Cardiol (Rome). 2012 Nov;13(11):734-40. doi: 10.1714/1168.12949. G Ital Cardiol (Rome). 2012. PMID: 23096582 Review. Italian.
Cited by
-
Preserved Skeletal Muscle Mitochondrial Function, Redox State, Inflammation and Mass in Obese Mice with Chronic Heart Failure.Nutrients. 2020 Nov 4;12(11):3393. doi: 10.3390/nu12113393. Nutrients. 2020. PMID: 33158222 Free PMC article.
-
Nurses' perspectives on the barriers to and facilitators of the implementation of secondary prevention for people with coronary heart disease: a qualitative descriptive study.BMJ Open. 2022 Sep 26;12(9):e063029. doi: 10.1136/bmjopen-2022-063029. BMJ Open. 2022. PMID: 36167370 Free PMC article.
-
Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus.BMC Cardiovasc Disord. 2014 Jan 9;14:4. doi: 10.1186/1471-2261-14-4. BMC Cardiovasc Disord. 2014. PMID: 24406095 Free PMC article.
-
Comparison of Incremental Shuttle Walking Test, 6-Minute Walking Test, and Cardiopulmonary Exercise Stress Test in Patients with Myocardial Infarction.Med Sci Monit. 2022 Oct 17;28:e938140. doi: 10.12659/MSM.938140. Med Sci Monit. 2022. PMID: 36245105 Free PMC article.
-
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.Pharmacoeconomics. 2007;25(12):1031-53. doi: 10.2165/00019053-200725120-00005. Pharmacoeconomics. 2007. PMID: 18047388 Review.
References
-
- Department of Health National Service Framework for coronary heart disease. London: Department of Health, 2000
-
- National Institute for Clinical Excellence Prophylaxis for patients who have experienced a myocardial infarction. London: NICE, 2001
-
- National Institute for Clinical Excellence TA039: Bupropion and nicotine replacement therapy. London: NICE, 2002
-
- National Institute for Health and Clinical Excellence PHI001: Brief interventions and referral for smoking cessation in primary care and other settings. London: NICE, 2006
-
- National Institute for Health and Clinical Excellence Clinical guideline 43: Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London: NICE, 2006 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical